A
Athira Pharma, Inc. (ATHA)
NCM – Real Time Price. Currency in USD
6.75
-0.44 (-6.12%)
At close: Jan 9, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
6.75
-0.44 (-6.12%)
At close: Jan 9, 2026, 4:00 PM EDT
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
| Name | Position |
|---|---|
| Dr. Javier San Martin M.D. | Chief Medical Officer |
| Dr. Kevin Church Ph.D. | Chief Scientific Officer |
| Dr. Mark J. Litton M.B.A., Ph.D. | President, CEO & Director |
| Mr. Mark F. Worthington J.D. | General Counsel, Chief Compliance Officer & Corporate Secretary |
| Mr. Robert Renninger | Chief Financial Officer |
| Ms. Julie Rathbun | Head of Investor Relations |
There is no data to display